3 New Strong Buy Ratings from Top-Rated Analysts: 01/13/2026
All of these stocks have excellent Zen Ratings and strong analyst support:
- Enhabit (EHAB) benefits from increased hospice demand
- Anaptysbio Inc (ANAB) hits a major catalyst
- HF Sinclair (DINO) sharpens its earnings profile
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
1. Enhabit (NYSE: EHAB)
Enhabit Inc is emerging as a healthcare standout — ranking #3 in its industry and benefiting from powerful demand tailwinds in home health and hospice care.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $10.05 — get current quote
Max 1-year forecast: $12.00
Why we're watching:
- Analyst support: Admittedly, EHAB only has one rating right now among the analysts we track — but it’s a bullish Strong Buy, with a price target that suggests over 20% potential upside. See the ratings
- The company is currently experiencing increasing market demand for medical care facilities, with strategic initiatives expected to enhance profitability and operational efficiencies throughout 2026.
- Industry ranking context: EHAB is currently the 3rd highest-rated stock out of 42 in the Medical Care Facility industry, which has an Industry Rating of A.
- With its Zen Rating of A (Strong Buy), EHAB is in a class of stocks that have historically delivered 32.52% annual returns — a testament to its growth potential in the expanding home healthcare market.
- Component Grades: EHAB has an exceptional Growth (A) grade combined with strong Safety (B) and Financials (B) scores, which demonstrate the company's balanced risk-reward profile. See all 7 Zen Component Grades here
2. Anaptysbio (NASDAQ: ANAB)
AnaptysBio just hit a major catalyst, submitting an FDA Biologics License Application for a leading drug in Generalized Pustular Psoriasis.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $45.00 — get current quote
Max 1-year forecast: $100.00
Why we're watching:
- Analyst support: 9 analysts we track cover the stock. It currently has 6 Strong Buy, 2 Buy, and 1 Hold ratings, demonstrating strong buy-side conviction. See the ratings
- UBS researcher Michael Yee (a top 19% rated analyst) recently assumed coverage with a Strong Buy rating and $70.00 price target (+56.70% upside), highlighting improving biotech fundamentals and anticipating a successful 2026 as investor confidence rebounds.
- Barclays' Etzer Darout (top 4%) maintains Strong Buy at $55.00, while Guggenheim's Yatin Suneja (top 4%) also rates it Strong Buy, reflecting consensus among top-tier analysts.
- Industry ranking context: While ANAB ranks an impressive 13 out of 490 stocks in the Biotech industry, it’s worth noting that the industry has a dismal F rating. Find out more about Industry Ratings here.
- Zen Rating highlights: As an A (Strong Buy) rated stock in the Zen Ratings, ANAB shows exceptional attributes based on our 115-factor review, which suggests near-term success for the stock.
- Component Grades: Strong Value (B), Growth (B), Momentum (B), and exceptional Sentiment (A) grades showcase both fundamental strength and positive market perception around ANAB. See all 7 Zen Component Grades here
3. HF Sinclair (NYSE: DINO)
HF Sinclair Corporation is sharpening its earnings profile by cutting 2026 capex while expanding higher-margin lubricants and specialty products through smart acquisitions.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $50.33 — get current quote
Max 1-year forecast: $68.00
Why we're watching:
- Analyst support: 9 analysts covering the stock with 5 Strong Buy, 2 Buy, and 2 Hold ratings, reflecting strong conviction across Wall Street. See the ratings
- Piper Sandler researcher Ryan Todd (a top 11% rated analyst) recently upgraded to Strong Buy with a $68.00 price target, representing +35.19% upside potential.
- Mizuho's Nitin Kumar (top 5%) maintains a Buy rating at $63.00, while Raymond James' Justin Jenkins (top 1%) reiterates Strong Buy at $65.00, highlighting broad-based analyst enthusiasm.
- Industry ranking context: DINO is currently the 3rd highest-rated stock in the Oil & Gas Refining & Marketing industry, which has an Industry Rating of A.
- Zen Rating highlights: A (Strong Buy) stocks average +32.52%/yr — ranks in top 15% of tracked stocks with strong earnings growth prospects of +147.63% next year.
- Component Grades: Strong Value (top 20%), Growth (top 15%), and Financials (top 35%) percentiles reflect DINO's attractive valuation at 23.62x P/E combined with 18.11% ROE and solid cash generation. See all 7 Zen Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.